⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CORT News
Corcept Therapeutics Inc.
CORT Shareholder Alert: April 21, 2026 Lead Plaintiff Deadline in Corcept Therapeutics Incorporated Securities Class Action Lawsuit — The Gross Law Firm
globenewswire.com
CORT
Pomerantz LLP Issues Reminder to Shareholders in Corcept Therapeutics Incorporated of Class Action Lawsuit – CORT
accessnewswire.com
CORT
CORT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
accessnewswire.com
CORT
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit
prnewswire.com
CORT
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action – CORT
globenewswire.com
CORT
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
prnewswire.com
CORT
Onco360® Has Been Selected as the National Pharmacy Partner for LIFYORLI™ (relacorilant)
globenewswire.com
CORT
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
accessnewswire.com
CORT
Deadline Alert: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
globenewswire.com
CORT
La FDA aprobó Lifyorli™ (relacorilant), el antagonista selectivo del receptor de glucocorticoides de Corcept, en combinación con nab-paclitaxel para el tratamiento de pacientes con cáncer de ovario resistente al platino
businesswire.com
CORT